Anand D. Patel, MD | Authors


Dramatic Response to Olaparib in a Patient With Metastatic Castration- Resistant Prostate Cancer

May 02, 2018

Molecular tumor profiling is rapidly driving personalized medicine within oncology. The value of identifying a targetable mutation using next-generation sequencing for available therapies or clinical trials cannot be underestimated. Herein, we review essential considerations in the initial assessment, specialty referral, and sequencing of treatment for advanced prostate cancer with an identified actionable mutation.